Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Viral conjunctivitis is an inflammation of the conjunctiva. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pink eye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.

Global Viral Conjunctivitis Drugs Market - Impact of the Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as a pandemic on March 11, 2020.

According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 166,346,635 cases and 3,449,117 deaths due to coronavirus disease (COVID-19) were reported till May 21, 2021, across the globe.

Impact of COVID-19 on Demand and Supply of Viral Conjunctivitis Drugs

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector which has been majorly impacted by the pandemic.

The COVID-19 pandemic has impacted the entire supply chain of the pharmaceutical industry mainly due to strict lockdown in several regions. However, the demand for conjunctivitis drugs is increasing in this COVID-19 pandemic, owing to rising number of conjunctivitis cases reported, in which conjunctivitis was the only symptom in COVID-19 positive patients.

Moreover, coronavirus pandemic has impacted development, production, and supply of medicines and affected businesses of various companies operating in the healthcare sector across the globe. The pandemic has led to the closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of products.

Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets

The supply chain and manufacturing activities in India, China, U.S., and other countries have been disrupted due to lockdown while countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation of drugs and medical devices.

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global viral conjunctivitis drugs market during the forecast period, owing to the decrease in the production and supply of the drugs during the pandemic.

The global viral conjunctivitis drugs market is estimated to be valued at US$ 293.7 Mn in 2021, and is expected to exhibit a CAGR of 4.7% over the forecast period (2021-2028).

Figure 1: Global Viral Conjunctivitis Drugs Market Share (%) Analysis, By Virus Type, 2021

Viral Conjunctivitis Drugs  | Coherent Market Insights

The increasing number of viral conjunctivitis cases is expected to drive the market growth over the forecast period.

The rising number of viral conjunctivitis cases is expected to drive growth of viral conjunctivitis drugs market over the forecast period. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S.

Moreover, increasing number of research and development activities for improving the effectiveness of viral conjunctivitis drugs is expected to aid in the growth of the market over the forecast period. For instance, in 2019, iVIEW Therapeutics Inc., a clinical stage ophthalmology drug development company, announced the dosing of the first patient in the Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis.

The rising healthcare expenditure may support research and development activities, which in turn may support the research and development of new drugs for viral conjunctivitis due to its increasing prevalence. This is expected to drive the growth of the global vial conjunctivitis drugs market over the forecast period. For instance, according to the Research America 2018 report, the U.S. government invested around 4.97% of the country’s GDP in the medical and health research & development sector in 2016, this increased to 5.03% in 2017. Moreover, according to the National Bureau of Statistics: February 2018, China’s expenditure on research and development increased by 11.6% in 2017 from 10.6% in 2016, accounting for US$ 280 Mn in 2017.

request-sample

Viral Conjunctivitis Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 293.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 4.7% 2028 Value Projection: US$ 405.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Artificial tears, Decongestants, Anti-histamines, NSAIDS, Anti-Viral drugs, Steroids, Antibiotics
  • By Virus Type: Adenovirus, Enterovirus, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.

Growth Drivers:
  • Increasing Access to Diagnostic Tests for Viral Conjunctivitis
  • Increasing Research and Development Activities by the Market Players
  • Increasing strategic collaborations among the market players
  • Increasing Product Launches and Approvals
  • Rising healthcare expenditure
Restraints & Challenges:
  • Increasing Product Recalls
  • Unavailability of Proper Anti-viral Treatment

Global Viral Conjunctivitis Drugs Market – Restraints

Growth of the viral conjunctivitis drugs market may be hampered, owing to the increasing product recalls, and unavailability of proper anti-viral treatment. According to the study published in Ophthalmology: 2017, an estimated 83% patients suffering from conjunctivitis visited primary care centers instead of ophthalmologist. The primary care physicians prescribe antibiotics for the treatment of conjunctivitis. Frequently prescribed antibiotics without good indication could present an unnecessary financial burden on the patient and increase the occurrence of drug-resistant disease-causing pathogens as well.

Moreover, according to the article published by American Academy for Ophthalmology: April 22, 2021, the antibiotic drops are not much effective in the treatment of viral conjunctivitis. The rates of antibiotic treatment in the community for patients suffering from infectious conjunctivitis in the U.K. ranges between 80% and 95%. Therefore, the success of clinical trials and the commercialization of the products for the treatment of viral conjunctivitis, will drive growth of the viral conjunctivitis drugs market.

Global Viral Conjunctivitis Drugs Market – Regional Analysis

On the basis of region, the global viral conjunctivitis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global viral conjunctivitis drugs market over the forecast period, owing to rising number of product launches. For instance, on February 23, 2021, Bausch + Lomb launched Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. It is indicated to relieve eye itchiness caused due to conjunctivitis. Moreover, it is the first over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the U.S. Food and Drug Administration (FDA).

Key players are focused on receiving patent for their products indicated for the treatment of treatment of conjunctivitis, which are expected to drive growth of the market in Asia Pacific. For instance, in 2018, Starpharma Holdings Limited, a company headquartered in Australia, received patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. The patent term is till 2033.

Figure 2: Global Viral Conjunctivitis Drugs Market Value (US$ Mn), by Region, 2021

Viral Conjunctivitis Drugs  | Coherent Market Insights

Global Viral Conjunctivitis Drugs Market – Competitive Landscape

Major players operating in the global viral conjunctivitis drugs market include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC – an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study:

  • This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market

Detailed Segmentation:

  • Global Viral Conjunctivitis Drugs Market, By Drug Class:
    • Artificial tears
    • Decongestants
    • Anti-histamines
    • NSAIDS
    • Anti-Viral drugs
    • Steroids
    • Antibiotics
  • Global Viral Conjunctivitis Drugs Market, By Virus Type:
    • Adenovirus
    • Enterovirus
    • Others
  • Global Viral Conjunctivitis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Viral Conjunctivitis Drugs Market, By Region:
    • North America
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
    • Middle East
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Artificial tears
        • Decongestants
        • Anti-histamines
        • NSAIDS
        • Anti-Viral drugs
        • Steroids
        • Antibiotics
      • By Virus Type:
        • Adenovirus
        • Enterovirus
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Takeda Pharmaceutical Company Limited
    • Bausch Health Companies Inc.
    • Panoptes Pharma Ges.m.b.H
    • NovaBay Pharmaceuticals, Inc.
    • Nicox
    • NanoViricides Inc.
    • Novartis International AG
    • Pfizer Inc.
    • Johnson & Johnson
    • GlaxoSmithKline Plc.
    • Okogen Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Virus Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Algorithm for Clinical Approach to Suspected Acute Conjunctivitis
    • Associated/Predisposing Factors for and Typical Clinical Signs Of Conjunctivitis
    • PEST Analysis
    • Recommendations for Other Eye Disorder Treatment
    • Industry Trends
    • Pipeline Analysis
    • Key Highlights
    • Epidemiology
    • Algorithm for Classification of Viral Conjunctivitis based on Clinical Presentation
    • Drugs Pricing List
    • Reimbursement Scenario of Viral Conjunctivitis Drugs
    • Regulatory Scenario
    • Global Supply Chain Analysis
  4.  Global Viral Conjunctivitis Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact of COVID-19 on Demand and Supply of Viral Conjunctivitis Drugs
    • Impact of Covid-19 on the Conjunctivitis Drugs Market
  5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2017-2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Artificial tears
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Decongestants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Anti-histamines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • NSAIDS
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Anti-viral drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Steroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Antibiotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Adenovirus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Enterovirus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 - 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global Viral Conjunctivitis Drugs Market, By Region, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Virus Type, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Panoptes Pharma Ges.m.b.H
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • NovaBay Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Nicox
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • NanoViricides Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • CuraMedical B.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategie
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Okogen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33  market data tables and 25 figures on "Viral Conjunctivitis Drugs Market” - Global Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The global viral conjunctivitis drugs market is expected to exhibit a CAGR of 4.7% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 293.7 Mn in 2021.
AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc., are some of the prominent players operating in the market.
The market is expected to be valued at US$ 405.2 Mn in 2028.
North America is the prominent region in the market.
Increasing number of product launches, rising cases of viral conjunctivitis, increasing research and development activities by the market players, and increasing strategic collaborations among the market players are some of the driving factors, which are expected to drive growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner